Attributable causes of chronic kidney disease in adults: a five-year retrospective study in a tertiary-care hospital in the northeast of the Malaysian Peninsula

Salman, Muhammad; Khan, Amer Hayat; Adnan, Azreen Syazril; Sulaiman, Syed Azhar Syed; Hussain, Khalid; Shehzadi, Naureen; Jummaat, Fauziah

doi:10.1590/1516-3180.2015.005

Cited by 12 publications

(7 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The current study also showed that the patients with CKD were older with co-morbidities, such as ischaemic heart disease (IHD) or stroke. Diabetes mellitus remains the most common cause of CKD, in agreement with the registry of this study (2,30).…”

Section: Discussionsupporting

confidence: 91%

“…Hypertension (HPT) is very common among patients with chronic kidney disease (CKD) with reported prevalence of as high as 80% to 90% (1); it can be the cause or the effect of CKD itself. Hypertensive nephrosclerosis was the second leading cause of CKD in Malaysia (24.2%) (2). Conversely, CKD is the most common cause of secondary HPT (3).…”

Section: Introductionmentioning

confidence: 99%

“…In the USA, it has been estimated that hypertension occurs in 23.3% of non-CKD patients (4). The glomerular filtration rate (GFR) declines more rapidly in hypertensive patients after 40 years of age at the rate of 1.5 mL/min per 1.73 m 2 per year compared to 0.75 -1.00 mL/min per 1.73 m 2 per year in non-hypertensive counterparts (5).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prevalence of White Coat Hypertension in Patients with Chronic Kidney Disease

et al. 2018

View full text Add to dashboard Cite

Background: Achieving target blood pressure is important in retarding the progression of chronic kidney disease (CKD). Optimizing patient's hypertension solely based on clinic blood pressure could be harmful as it may be masked by white coat hypertension. Objectives: This study aimed at determining the prevalence of white coat hypertension (WCHT) in patients with CKD and correlating this with their target organ damage evidenced by left ventricular hypertrophy (LVH) and carotid intima media thickness (CIMT). Methods: A cross sectional study of 99 patients with CKD (stage 3 to 5 with eGFR Epi of < 60 mL/min/1.732) at a CKD clinic was conducted. Demographic data, routine blood investigations, and number of antihypertensive medication were recorded. Mean clinic blood pressure of the last 2 visits were taken followed by 24-hour ambulatory blood pressure monitoring (24-hour ABPM), electrocardiography, and carotid ultrasound measurement. Results: Ninety-nine patients (42 males and 57 females) with median age of 62 (55 to 69) years old and predominantly Malays ethnicity were recruited. The prevalence of WCHT was 34.3% (34 patients), and 65.7% (65 patients) had sustained hypertension (SHT). Median eGFRs were comparable in both groups (P = 0.479). Despite comparable mean clinic blood pressure (P = 0.85), the WCHT group had significantly lower mean average systolic, daytime, and night time blood pressure when compared with the SHT group

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of White Coat Hypertension in Patients with Chronic Kidney Disease

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In without CKD group 9 (18.0%) had HTN, 6 (12.0%) had DM. Salman et al (2015) 16 in their study reported the most frequent attributable cause of CKD was diabetic nephropathy (44.9%), followed by hypertension (24.2%), obstructive uropathy (9.2%), glomerulonephritis (6.7%). They also reported CKD was unknown in 9.4% of their cases.…”

Section: Discussionmentioning

confidence: 94%

Serum Cystatin C as an Endogenous Marker of Renal Function in Patients with Chronic Kidney Disease (CKD)

et al. 2018

View full text Add to dashboard Cite

Background: Cystatin C is being considered as a potential replacement for serum creatinine as a filtration marker. Objectives: This present study was conducted to determine the validity of Cystatin C as a renal function test and to compare the Cystatin C and serum creatinine level between the CKD cases and person not having CKD. Methodology: The present case control study was conducted in the department of Nephrology of Dhaka Medical College Hospital during the period of January 2009 to December 2009 with the aim to find out the serum Cystatin C as diagnostic markers of chronic kidney disease. In the present study total 100 respondents were included. Among them 50 were CKD patients and another 50 were without CKD. Results: It was an age and sex matched study. Out of 50 patients with CKD, 29 (58.0%) were in the stage IV followed by 15 (30.0%) were in the stage III and rest 6 (12.0%) were in the stage V. In CKD group 31 (62.0%) had glomerulonephritis, 18 (36.0%) had HTN, 11 (22.0%) had DM and 3 (6.0%) had obstructive uropathy. In without CKD group 9 (18.0%) had HTN, 6 (12.0%) had DM. Mean±SD of Serum Creatinine in CKD and without CKD groups were 5.73±2.69 and 0.85±0.11mg/dl respectively. Mean±SD of Serum Cystatin C in CKD and without CKD groups were 3.59±1.21 and 0.71±0.09 mg/dl respectively. In all patients sensitivity of Cystatin C to diagnose CKD was 100.0% and specificity also100.0%. Sensitivity of serum creatinine to diagnose CKD was 88.0% and specificity was 100.0%. Conclusions: Cystatin C proved more reliable than creatinine and was comparable to plasma creatinine and Cockcroft-Gault estimation. Serum Cystatin C had higher diagnostic accuracy with high sensitivity and specificity to detect renal function and is a reliable marker of renal function.

show abstract

“…En cualquier caso, los servicios de prevención pueden mejorar, con énfasis en poblaciones de riesgo como pacientes con hipertensión o diabetes (15) . Esto puede ser particularmente relevante en Lima, ciudad que exhibe más prevalencia por estas dolencias crónicas, a las cuales se le puede atribuir el 44 % (nefropatía diabética) y 24 % de los casos de ERC (16) .…”

Section: Discussionunclassified

Mortalidad por enfermedad renal crónica en el Perú: tendencias nacionales 2003-2015

Carrillo‐Larco

Bernabé‐Ortiz

2018

Rev Peru Med Exp Salud Publica

View full text Add to dashboard Cite

Objetivos. Describir la tendencia de mortalidad por enfermedad renal crónica (ERC) en el Perú en el periodo 2003-2015. Materiales y Métodos. Análisis de datos secundarios y de diseño ecológico. Se analizaron registros nacionales de mortalidad basados en certificados de defunción. ERC fue definida como código CIE 10: N18 en la causa básica. Se describen frecuencias absolutas y relativas de muerte por ERC. Para estimar la proporción de muertes por ERC en cada región del Perú, se utilizó un modelo lineal mixto generalizado. La variable desenlace fue la proporción de muertes, las variables independientes fueron cada región del país y el año. Resultados. El análisis incluyó 1 086 778 defunciones, de los cuales 25 091 (2,0 % ajustado por edad y sexo) fueron por ERC. Durante el periodo de estudio la edad promedio, al momento del fallecimiento, aumentó en 2,6 años (p<0,001); además, la proporción de muertes por ERC ajustada por edad y sexo fue siempre mayor en mujeres. En el periodo de observación la región con mayor mortalidad por ERC fue Puno (4,1 %), y con menor mortalidad fue Amazonas (1,1 %). Aquellas regiones que mostraron un aumento significativamente mayor que las demás fueron Tacna,

show abstract

Attributable causes of chronic kidney disease in adults: a five-year retrospective study in a tertiary-care hospital in the northeast of the Malaysian Peninsula

Cited by 12 publications

References 16 publications

Prevalence of White Coat Hypertension in Patients with Chronic Kidney Disease

Prevalence of White Coat Hypertension in Patients with Chronic Kidney Disease

Serum Cystatin C as an Endogenous Marker of Renal Function in Patients with Chronic Kidney Disease (CKD)

Mortalidad por enfermedad renal crónica en el Perú: tendencias nacionales 2003-2015

Contact Info

Product

Resources

About